Journal article
Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2 ve breast cancer metastasis
A Nagpal, RP Redvers, X Ling, S Ayton, M Fuentes, E Tavancheh, I Diala, A Lalani, S Loi, S David, RL Anderson, Y Smith, D Merino, D Denoyer, N Pouliot
Breast Cancer Research | BMC | Published : 2019
Abstract
Background: Human epidermal growth factor receptor-2 (HER2)-targeted therapies prolong survival in HER2-positive breast cancer patients. Benefit stems primarily from improved control of systemic disease, but up to 50% of patients progress to incurable brain metastases due to acquired resistance and/or limited permeability of inhibitors across the blood-brain barrier. Neratinib, a potent irreversible pan-tyrosine kinase inhibitor, prolongs disease-free survival in the extended adjuvant setting, and several trials evaluating its efficacy alone or combination with other inhibitors in early and advanced HER2-positive breast cancer patients are ongoing. However, its efficacy as a first-line thera..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported in part by a project grants from the National Breast Cancer Foundation (#IN-16-036) to NP, SL and RLA and IIRS-19-046 to NP, SA, DD, RLA and SL; a Lew Carty Foundation grant to SD; a La Trobe University Research Focus Area grant to NP; a National Health & Medical Research Council (NHMRC #1050384) to RLA; a Career Fellowship from the National Breast Cancer Foundation (NBCF) to RLA; and a Cancer Australia grant (#1067045) to RLA and NP. AN and MF were supported by La Trobe University Post Graduate Research Scholarships (LTUPRS/LTUFFRS). ET was supported by a humanitarian scholarship from the College of Health, Science and Engineering, La Trobe University.